Lucid Diagnostics (LUCD) vs TransMedics Group (TMDX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
TransMedics Group (TMDX) has outperformed Lucid Diagnostics (LUCD) over the past year, losing 33.1% versus a loss of 46.7%. Over five years, TMDX leads with a +197.6% price change compared with -93.0% for LUCD. TransMedics Group is the larger company by market cap ($2.74 billion vs $124.1 million), about 22.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LUCD | TMDX |
|---|---|---|
| Share price | $0.6501 | $79.00 |
| Market cap | $124.14M | $2.74B |
| 1-day change | +4.27% | -2.55% |
| YTD return | -40.36% | -35.06% |
| 1-year return | -46.71% | -33.08% |
| 5-year return | -93.05% | +197.55% |
| P/E ratio (TTM) | — | 20.47 |
| Forward P/E | — | 35.05 |
| EPS (TTM) | $-0.44 | $3.86 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $605.49M |
| Revenue growth (YoY) | — | +37.13% |
| Net income (latest FY) | — | $190.29M |
| Gross margin | — | 59.92% |
| Operating margin | — | 17.93% |
| Net margin | — | 31.43% |
| 52-week high | $1.63 | $156.00 |
| 52-week low | $0.50 | $60.11 |
| Distance from 52-week high | -60.09% | -49.36% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +515.29% | +26.35% |
| Average volume | 1.35M | 820.41K |
| Shares outstanding | 190.95M | 34.68M |
| Employees | 82 | 898 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TransMedics Group is about 22.1 times larger than Lucid Diagnostics by market value ($2.74B vs $124.14M).
- TMDX has outperformed LUCD by 13.6 percentage points over the past year.
About Lucid Diagnostics
LUCD stock →Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States.
Health Care · Medical/Dental Instruments · 82 employees
About TransMedics Group
TMDX stock →TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 898 employees
LUCD vs TMDX FAQ
Which is bigger, Lucid Diagnostics or TransMedics Group?
TransMedics Group (TMDX) is larger, with a market capitalization of $2.74B compared with $124.14M for Lucid Diagnostics (LUCD).
Which stock has performed better over the past year, LUCD or TMDX?
TMDX returned -33.08% over the past 12 months, compared with -46.71% for LUCD (price return, excluding dividends). Past performance does not predict future results.
Are Lucid Diagnostics and TransMedics Group in the same industry?
Both are in the Health Care sector, but in different industries: Medical/Dental Instruments for Lucid Diagnostics and Biotechnology: Electromedical & Electrotherapeutic Apparatus for TransMedics Group.